Pd29-09 Prostate Cancer and Solid Organ Transplantation: Patient Management and Outcomes

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I (PD29)1 May 2024PD29-09 PROSTATE CANCER AND SOLID ORGAN TRANSPLANTATION: PATIENT MANAGEMENT AND OUTCOMES Alon Lazarovich, Tanya W. Kristof, Aaron Dahmen, Shavano Steadman, Todd Morgan, and Scott Eggener Alon LazarovichAlon Lazarovich , Tanya W. KristofTanya W. Kristof , Aaron DahmenAaron Dahmen , Shavano SteadmanShavano Steadman , Todd MorganTodd Morgan , and Scott EggenerScott Eggener View All Author Informationhttps://doi.org/10.1097/01.JU.0001008736.23117.7f.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The impact of organ transplantation and associated immunosuppression on the incidence, progression, and mortality of prostate cancer remains an area of substantial clinical uncertainty. Our primary objective was to analyze the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation. METHODS: We conducted a retrospective analysis of patients from the University of Chicago and the University of Michigan who had solid organ transplantation and were diagnosed with prostate cancer before or after organ transplantation. Data collected included demographics and clinical information. RESULTS: The cohort consisted of 110 patients with a median (IQR) age at prostate cancer diagnosis of 62 (56.6-67.2) years and a median (IQR) age at transplantation of 58.6 (52.7-65.3) years. Kidney transplants were the most common (53.6%), followed by heart (24.5%), liver (11.8%), and lung (4.5%). At the time of prostate cancer diagnosis, the median (IQR) PSA was 6.2 ng/ml (4.5-10), and the distribution of NCCN risk groups was: low-risk (35.5%), intermediate-risk (50%), and high-risk (14.5%). Forty-five (40.9%) patients were diagnosed with prostate cancer prior to transplantation and had a median (IQR) interval between diagnosis and transplant of 4.7 (2-6.8) years. Management included radical prostatectomy (RP) (62.2%), external beam radiotherapy (XRT) (13.3%), active surveillance (AS) (17.8%) and other (6.7%). During a median (IQR) follow-up of 5.8 (2.5-10) years, one (2.2%) patient (intermediate risk, initially treated with RP) developed metastatic disease. Sixty-five (59.1%) patients who were diagnosed with prostate cancer subsequent to organ transplantation had a median (IQR) interval of 7.3 (3.6-11.8) years between transplant and diagnosis. Management included AS (29.2%), XRT (44.7%), RP (15.3%) and other (10.8%). During a median (IQR) follow-up of 5.3 (1-8.4) years, 2 patients (4.3%) developed metastatic disease (1 patient with high risk and 1 with intermediate risk disease, both of them were initially treated with XRT). There were no deaths from prostate cancer. CONCLUSIONS: Our study suggests a diagnosis of localized prostate cancer should not preclude solid organ transplantation and the presence of a transplant does not appear to significantly affect prostate cancer progression. Furthermore, these data support the safety of active surveillance in appropriately selected patients with a solid organ transplant. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e622 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Alon Lazarovich More articles by this author Tanya W. Kristof More articles by this author Aaron Dahmen More articles by this author Shavano Steadman More articles by this author Todd Morgan More articles by this author Scott Eggener More articles by this author Expand All Advertisement PDF downloadLoading ...